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Atherosclerosis is a chronic inflammatory process with increased oxida-
tive stress in vascular endothelium. Ginkgo biloba extract (GbE), ex-
tracted from Ginkgo biloba leaves, has commonly been used as a
therapeutic agent for cardiovascular and neurological disorders. The aim
of this study was to investigate how GbE protects vascular endothelial
cells against the proatherosclerotic stressor oxidized low-density lipopro-
tein (oxLDL) in vitro. Human umbilical vein endothelial cells (HUVECs)
were incubated with GbE (12.5–100 g/ml) for 2 h and then incubated
with oxLDL (150 g/ml) for an additional 24 h. Subsequently, reactive
oxygen species (ROS) generation, antioxidant enzyme activities, adhe-
sion to monocytes, cell morphology, viability, and several apoptotic
indexes were assessed. Our data show that ROS generation is an upstream
signal in oxLDL-treated HUVECs. Cu,Zn-SOD, but not Mn-SOD, was
inactivated by oxLDL. In addition, oxLDL diminished expression of
endothelial NO synthase and enhanced expression of adhesion mol-
ecules (ICAM, VCAM, and E-selectin) and the adherence of mono-
cytic THP-1 cells to HUVECs. Furthermore, oxLDL increased intra-
cellular calcium, disturbed the balance of Bcl-2 family proteins,
destabilized mitochondrial membrane potential, and triggered subse-
quent cytochrome c release into the cytosol and activation of
caspase-3. These detrimental effects were ameliorated dose depen-
dently by GbE (P  0.05). Results from this study may provide
insight into a possible molecular mechanism underlying GbE suppres-
sion of the oxLDL-mediated vascular endothelial dysfunction.
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ELEVATED LEVELS OF OXIDIZED low-density lipoprotein (oxLDL)
are considered to be one of the major risk factors for athero-
sclerosis and cardiovascular morbidity (49). OxLDL has been
detected in atherosclerotic lesions and is thought to play a
major role in the initiation and progression of atherosclerosis
(55). The morphological changes of cultured endothelial cells
associated with oxLDL toxicity are similar to those observed in
vivo in endothelial cells covering atherosclerotic areas (41).
Reactive oxygen species (ROS) derived from NADPH oxidase
have been shown to be strongly associated with atherosclerosis
(51). Chen et al. (7) further revealed that oxLDL-induced
apoptosis was prevented by radical-scavenging agents and
NADPH oxidase inhibitor. The early stages of the atheroscle-
rotic process are initiated by accumulation of oxLDL and
activation of endothelial cells with subsequent expression of
adhesion molecules and increased binding of monocytes to the
vascular endothelium (45). Proinflammatory cytokines, such as
IL-1 and TNF-, which are released when endothelial cells are
exposed to oxLDL, upregulate the expression of cell adhesion
molecules (39). This series of adverse changes also is associ-
ated with a decrease in the bioavailability of nitric oxide (NO),
a change that results in a reduced ability of the endothelium to
control vessel tone. In addition, oxLDL induces proliferation at
lower concentrations and shorter exposure times but induces
apoptosis or even necrosis at higher concentrations and longer
exposure times (15). It is believed that the induction of apop-
tosis involves several critical steps, including ROS genera-
tion, intracellular calcium accumulation, disturbance of
Bcl-2 family protein balance, and reduction of mitochon-
drial transmembrane potential with concomitant release of
mitochondrial protein cytochrome c and the subsequent
activation of caspase-3 (42).
Ginkgo biloba extract (GbE), a defined complex mixture
containing 24% ginkgo flavone glycoside and 6% terpenlac-
tones (ginkgolides, bilobalide), is extracted from the leaves of
the Ginkgo biloba tree. The flavonoids (ginkgo flavone glyco-
sides, bioflavonoids) and terpenoids (ginkgolides and bilob-
alide) in GbE have been found to possess antitumor (59),
antiaging (12), hepatoprotective (38), and cardioprotective
properties (50). It has been used clinically to treat dementia,
vaso-occlusive, and cochleovestibular disorders (12, 25). Re-
cent studies have shown that the potential benefits of Ginkgo
biloba in cardiovascular diseases are mediated through its
protective roles against free radical injury. GbE has been
shown to inhibit P-selectin-mediated leukocyte adhesion and
inflammation (14), scavenge various free radicals (38), in-
crease endothelial NO production, prolong its half-life by the
destruction of superoxide radicals on the vascular endothelium
(22), and suppress Toll-like receptor 4 expression and NADPH
oxidase activation (28).
Although GbE has been shown to have an antioxidant effect
both in vivo and in vitro, to the best of our knowledge, there are
no studies of these effects on oxLDL-induced endothelial
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dysfunction. Therefore, in this study, we tested the hypothesis
that GbE could protect against oxLDL-induced endothelial
dysfunction by downregulating ROS generation. We undertook
the current study to explore the effects of GbE on oxLDL-
induced expression of endothelial NO synthase (eNOS) and
adhesion molecules and on oxLDL-induced adhesion of mono-
cytes. Furthermore, we also investigated several apoptotic
features, such as the accumulation of intracellular calcium and
mitochondrial destabilization and the activation of caspase.
MATERIALS AND METHODS
Reagents. Fetal bovine serum (FBS), medium 199 (M199), and
trypsin-EDTA were obtained from GIBCO (Grand Island, NY). Low-
serum growth supplement (Cascade Biologics, Portland, OR), 2,7-
bis(2-carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl ester
(BCECF-AM), 4,6-diamidino-2-phenylindole (DAPI), EDTA, peni-
cillin, and streptomycin were obtained from Sigma (St. Louis, MO).
GbE, a defined complex mixture containing 24% ginkgo flavone
glycoside (primarily composed of quercetin, kaempferol, and isorh-
amnetin) and 6% terpenlactones (ginkgolides A, B, and C and bilob-
alide) extracted from Ginkgo biloba leaves, was obtained from Dr.
Willmar Schwabe (Karlsruhe, Germany). Lactate dehydrogenase
(LDH) kits and the terminal deoxynucleotidyl transferase dUTP-
mediated nick-end labeling (TUNEL) staining kit were obtained from
Boehringer Mannheim (Mannheim, Germany). The superoxide dis-
mutase activity assay kit was purchased from Calbiochem (San Diego,
CA). Dihydroethidium (DHE) and the EnzChek caspase-3 assay kit
were purchased from Molecular Probes (Eugene, OR). 5,58,6,68-
tetraethylbenzimidazolcarbocyanine iodide (JC-1) and anti-active
caspase 3 were obtained from BioVision (Palo Alto, CA). Anti-
vascular cell adhesion molecule-1 (VCAM-1), anti-intercellular adhe-
sion molecule (ICAM), and anti-E-selectin were purchased from R&D
Systems (Minneapolis, MN). Anti-Cu,Zn superoxide dismutase
(SOD-1) and anti-Mn superoxide dismutase (SOD-2) were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-eNOS, anti-
Bcl-2, and anti-Bax were obtained from BD Transduction Laborato-
ries (San Diego, CA).
Cell cultures. This experiment was approved by the Research
Ethics Committee of Taichung Veterans General Hospital. With the
written consent of the parents, fresh human umbilical cords were
obtained after birth, collected, and suspended in Hanks’ balanced salt
solution (GIBCO) at 4°C. Human umbilical vein endothelial cells
(HUVECs) were isolated from human umbilical cord with collagenase
and used at passages 2 and 3 (19). After dissociation, the cells were
collected and cultured on gelatin-coated culture dishes in M199 with
low-serum growth supplement, 100 IU/ml penicillin, and 0.1 mg/ml
streptomycin. Subcultures were performed with trypsin-EDTA. Media
were refreshed on every second day. The identity of umbilical vein
endothelial cells was confirmed by their cobblestone morphology and
strong positive immunoreactivity to von Willebrand factor. THP-1, a
human monocytic leukemia cell line, was obtained from American
Type Culture Collection (Rockville, MD) and cultured in RPMI with
10% FBS at a density of 2–5  106 cells/ml as suggested in the
product specification sheet provided by the manufacturer.
Lipoprotein separation. Human plasma was obtained from the
Taichung Blood Bank, and LDL was isolated using sequential ultra-
centrifugation (  1.019–1.210 g/ml) in KBr solutions containing 30
mM EDTA, stored at 4°C in a sterile, dark environment, and used
within 3 days (17). Immediately before the oxidation tests, LDL was
separated from EDTA and from diffusible low-molecular mass com-
pounds by gel filtration on PD-10 Sephadex G-25 M gel (Pharmacia)
in 0.01 M phosphate-buffered saline (136.9 mM NaCl, 2.68 mM KCl,
4 mM Na2HPO4, and 1.76 mM KH2PO4, pH 7.4). Cu2-modified
LDL (1 mg protein/ml) was prepared by exposing LDL to 10 M
CuSO4 for 16 h at 37°C. Protein was measured by the method used by
Bradford (4).
Measurement of ROS production. ROS, such as superoxide (O2	)
and hydrogen peroxide (H2O2), are specific mediators of atherogenic
stimuli that induce leukocyte adhesion to endothelial cells. In addi-
tion, the role that ROS plays in oxLDL-mediated cytotoxicity is
believed to be through the induction of apoptosis and the activation of
the caspase cascade (18). The effect of GbE on ROS production in
HUVECs was determined by performing a fluorometric assay using
DHE as a probe for the presence of superoxide. After preincubation
for 2 h with the indicated concentrations of GbE, HUVECs were
incubated with DHE for 1 h, followed by incubation with oxLDL for
the indicated time periods. The fluorescence intensity was measured at
540-nm excitation and 590-nm emission using a Labsystems fluores-
cence microplate reader. The percent increase in fluorescence per well
was calculated using the formula [(Ft2 	 Ft0)/Ft0]  100, where Ft2
is the fluorescence at 2 h of oxLDL exposure and Ft0 is the fluores-
cence at 0 min of oxLDL exposure.
Measurement of SOD activity. To determine the effect of GbE on
antioxidant enzyme after oxLDL treatment, SOD activity in the
homogenate was determined by an enzymatic assay method using a
commercial kit (Calbiochem) according to the manufacturer’s instruc-
tions. Enzyme activity was converted to units per milligram of
protein.
Immunoblotting. To determine whether GbE could ameliorate the
oxLDL-diminished SOD-1, SOD-2, eNOS, Bcl-2, and Bax protein
expression, HUVECs were grown to confluence, pretreated with GbE
for 2 h, and then stimulated with oxLDL for 24 h. At the end of
stimulation, cells were washed, scraped from dishes, and lysed in
RIPA buffer (in mM: 20 HEPES, 1.5 MgCl2, 2 EDTA, 5 EGTA, 0.1
DTT, and 0.1 PMSF, pH 7.5). Proteins (30 g) were then separated by
electrophoresis on SDS-polyacrylamide gel. After the proteins had
been transferred onto a polyvinylidene difluoride membrane (Milli-
pore, Bedford, MA), the blot was incubated with blocking buffer (1
PBS and 5% nonfat dry milk) for 1 h at room temperature and then
probed with primary antibodies (SOD-1, SOD-2, eNOS, Bcl-2, Bax;
1:1,000 dilutions) overnight at 4°C, followed by incubation with
horseradish peroxidase-conjugated secondary antibody (1:5,000) for
1 h. To control equal loading of total protein in all lanes, blots were
stained with mouse anti-
-actin antibody at a 1:50,000 dilution. The
bound immunoproteins were detected by an enhanced chemilumines-
cence assay (ECL; Amersham, Little Chalfont, UK), and the intensi-
ties were quantified by densitometric analysis (Digital Protein DNA
Imagineware, Huntington Station, NY).
Adhesion assay. HUVECs at 1  105 cells/ml were cultured in
96-well flat-bottom plates (0.1 ml/well) for 1–2 days. Cells were then
pretreated with the indicated concentrations of GbE for 2 h and
incubated with oxLDL (150 g/ml) for 24 h. The medium was then
removed, and 0.1 ml/well of THP-1 cells (prelabeled with 4 M
BCECF-AM for 30 min in RPMI at a 1  106 cell/ml density) was
added in RPMI. The cells were allowed to adhere at 37°C for 1 h in
a 5% CO2 incubator. The nonadherent cells were removed by gentle
aspiration. Plates were washed three times with M199. The number
of adherent cells was estimated by microscopic examination; the
cells were then lysed with 0.1 ml of 0.25% Triton X-100. The
fluorescence intensity was measured at 485-nm excitation and
538-nm emission using a Labsystems fluorescence microplate
reader.
Adhesion molecule expression. To determine whether GbE could
modify the oxLDL-induced adhesion molecule expression, HUVECs
were grown to confluence, pretreated with GbE for 2 h, and stimulated
with oxLDL (150 g/ml) for 24 h. At the end of stimulation,
HUVECs were harvested and incubated with FITC-conjugated anti-
VCAM-1, anti-ICAM-1, and anti-E-selectin (R&D Systems) for 45
min at room temperature. After the HUVECs had been washed three
times, their immunofluorescence intensity was analyzed by flow
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cytometry using a Becton Dickinson FACScan flow cytometer
(Mountain View, CA).
Measurement of intracellular calcium. To determine the effect of
GbE on the rise of oxLDL-induced intracellular calcium level
([Ca2]i), HUVECs were seeded onto 24-mm glass coverslips, pre-
treated with GbE for 2 h, and then stimulated with oxLDL (150
g/ml) for the indicated time periods. The cells on the coverslips were
loaded with 2 M fura-2 AM (Molecular Probes) in M199 and
allowed to stand for 30 min at 37°C. After loading, the cells were
washed with HEPES buffer (in mM: 131 NaCl, 5 KCl, 1.3 CaCl2, 1.3
Mg2SO4, 0.4 KH2PO4, 20 HEPES, and 25 glucose, pH 7.4) to remove
excess fluorescent dye. The fluorescence of the cells on each coverslip
was then measured and recorded using an inverted Olympus IX-70
microscope. [Ca2]i in endothelial cells was monitored at an emission
wavelength of 510 nm with excitation wavelengths alternating be-
tween 340 and 380 nm with the use of a Delta Scan System (Photon
Technology International, Princeton, NJ) and calculated using the
method of Grynkiewicz et al. (16).
Measurement of mitochondrial membrane potential. The lipophilic
cationic probe fluorochrome JC-1 was used to explore the effect of
GbE on the mitochondrial membrane potential (m). JC-1 exists as
either a green fluorescent monomer at depolarized membrane poten-
tials or a red fluorescent J-aggregate at hyperpolarized membrane
potentials. JC-1 exhibits potential-dependent accumulation in mito-
chondria, as indicated by the fluorescence emission shift from 530 to
590 nm. After cells were treated with oxLDL (150 g/ml) for 24 h in
the presence or absence of various concentrations of GbE, cells (5 
104 cells/24-well plate) were rinsed with M199, and JC-1 (5 M) was
loaded. After 20 min of incubation at 37°C, cells were examined
under a fluorescence microscope. Determination of the m was
carried out using a FACScan flow cytometer (3).
Isolation of cytosolic fraction for cytochrome c analysis. After cells
were treated with oxLDL in the presence and absence of GbE, the
cells were collected and lysed with lysis buffer (20 mM HEPES-
NaOH, pH 7.5, 250 mM sucrose, 10 mM KCl, 2 mM MgCl2, 1 mM
EDTA, 1 mM DTT, and protease inhibitor cocktail) for 20 min on ice.
The samples were homogenized by 10 passages through a 2-gauge
needle. The homogenate was then centrifuged at 12,000 rpm for 20
min at 4°C. Protein was measured using the Bradford method (4). A
volume of cell lysates containing 30 g of protein was analyzed by
Western blot analysis for cytochrome c (1:1,000) and 
-actin (1:
50,000).
Measurement of active caspase-3. To explore the effect of GbE on
oxLDL-induced caspase-3 activation, HUVECs were pretreated with
GbE for 2 h and then stimulated with oxLDL (150 g/ml) for 24 h.
The level of active caspase-3 was detected by flow cytometry using a
commercial fluorescein active caspase kit (Mountain View, CA) (48)
and a fluorescence microscope. Activity of caspase-3 also was mea-
sured using the EnzChek caspase-3 assay kit according to the manu-
facturer’s instructions (Molecular Probes). After being lysed by re-
peated freeze-thaw, cells were incubated on ice for 15 min and
centrifuged at 15,000 g for 20 min. The protein concentrations of the
supernatants were determined. Equal amounts of protein (50 g)
were added to the reaction buffer containing 5 mM of caspase-3
substrate Z-DEVD-R110, and the mixture was incubated at room
temperature for 30 min. The fluorescence generated from cleavage
of the substrate by caspase-3 was monitored with a Labsystems
fluorescence microplate reader at excitation and emission wave-
lengths of 496 and 520 nm, respectively.
Determination of cytotoxicity and indexes of apoptosis. To deter-
mine the effect of GbE on oxLDL-induced cytotoxicity, HUVECs
were first incubated with GbE for 2 h and then stimulated with
oxidized LDL for 24 h. At the end of stimulation, mitochondrial
dehydrogenase activity, which can be used as an index of cell
viability, was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium (MTT) assay (11). Plasma membrane integrity
was assessed by measuring LDH release using an LDH diagnostic kit
according to the manufacturer’s instructions. Apoptotic cells were
Fig. 1. Inhibitory effects of Ginkgo biloba extract (GbE) on oxidized low-density lipoprotein (oxLDL)-induced reactive oxygen species (ROS) production in
human umbilical vein endothelial cells (HUVECs). After preincubation for 2 h with 12.5–100 g/ml GbE (A), 1.25–10 M Trolox (B), and 1.55–12.4 g/ml
quercetin (C), 150 g/ml oxLDL was added to the medium for 2 h, followed by a 1-h incubation with the fluorescent probe dihydroethidium (DHE; 10 M).
Fluorescence intensity of cells was measured with a fluorescence microplate reader. Fluorescence distribution of DHE oxidation was expressed as a percentage
of increased intensity. D: the activities of SOD in HUVECs stimulated with oxLDL in the absence or presence of GbE were determined. E and F: representative
Western blots of Cu,Zn-superoxide dismutase (SOD-1) and Mn-SOD (SOD-2) protein levels in HUVECs pretreated with GbE for 2 h, followed by 150 g/ml
oxLDL for 24 h (E). Densitometric data are means  SE of 3 independent analyses (F). *P  0.05 compared with oxLDL-stimulated HUVECs.
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assessed by a TUNEL assay under a fluorescence microscope or in a
flow cytometer.
Statistical analyses. Results are means  SE, and data were
analyzed using one-way ANOVA followed by Student’s t-test for
significant difference. A P value 0.05 was considered statistically
significant.
RESULTS
GbE inhibited oxLDL-induced ROS generation in HUVECs.
A previous study demonstrated that oxLDL evoked a progres-
sive rise in cellular ROS, which subsequently led to the
activation of apoptotic signaling (43). We therefore investi-
gated the effects of GbE on the generation of ROS, a potential
factor related to oxLDL-induced endothelial cell injury, by
using DHE. Pretreatment of HUVECs with GbE (12.5–100
g/ml) for 2 h before exposure to 150 g/ml oxLDL signifi-
cantly decreased the level of ROS generation in a dose-
dependent manner (all P  0.05) (Fig. 1A). Preincubation of
HUVECs with Trolox (a potent antioxidant as a positive
control) similarly inhibited ROS generation caused by oxLDL
(Fig. 1B). The maximal inhibitory effect was achieved at 100
g/ml in GbE (95.6% inhibition, P  0.05) and at 10 M in
Trolox (104% inhibition, P  0.05), respectively. Since GbE
contains 24% ginkgo flavone glycoside, and its anti-inflamma-
tory and antioxidant activities depend on its various compo-
nents, such as quercetin, kaempferol, and isorhamnetin, all of
which have been used in previous studies with different effects
(2, 9), we decided to compare the efficacy of quercetin (a main
flavonoid component in GbE) and GbE on modulation of ROS
reduction. Our results suggested that quercetin at the concen-
trations of 1.55, 3.1, 6.2, and 12.4 g/ml, similar to that
contained in 12.5, 25, 50, and 100 g/ml GbE, was not as
potent as GbE in ROS reduction (Fig. 1C). Thus we believe
that quercetin probably is not the sole component responsible
for the in vitro inhibition of oxLDL-induced ROS generation
by GbE.
Intracellular ROS levels are regulated by the balance be-
tween ROS generation and antioxidant enzymes. In addition,
the involved ROS are able to inactivate antioxidative enzymes
that additionally increase the imbalance in favor of oxidative
stress. We next turned our attention to the total activity of SOD
and the expression of its isoforms in endothelial cells in
response to oxLDL. Our results showed that GbE at concen-
trations 25 g/ml significantly reduced the suppression of
SOD activity caused by oxLDL (Fig. 1D). SOD-1, but not
SOD-2, expression was diminished after treatment with
oxLDL for 24 h and could be significantly rescued by
pretreatment with GbE (Fig. 1, E and F).
GbE ameliorated oxLDL-diminished eNOS protein expres-
sion. OxLDL has been shown to reduce the release of NO from
endothelial cells, thereby causing endothelial dysfunction (37).
It also has been shown that GbE increases eNOS expression
(22). In this study, we examined whether GbE could rescue
eNOS protein expression after treatment with oxLDL. As
Fig. 2. Effects of GbE on oxLDL-impaired endothelial nitric oxide synthase
(eNOS) protein expression. HUVECs were pretreated for 2 h with indicated
concentrations of GbE, followed by 150 g/ml oxLDL for 24 h. For Western
blot analyses, a monoclonal anti-eNOS and a monoclonal anti-
-actin antibody
(for normalization) were used. Values are means  SE of 3 independent
analyses. *P  0.05 vs. oxLDL treatment.
Fig. 3. Effects of GbE on oxLDL-induced adhesiveness of HUVECs to THP-1
monocytic cells and adhesion molecule expression. Cells were incubated with
indicated concentrations of GbE for 2 h and then incubated with ox-LDL for
an additional 24 h. A: dose-dependent effect of GbE (12.5–100 g/ml) on
oxLDL (150 g/ml)-induced adhesiveness of HUVECs to THP-1 was mea-
sured as described in MATERIALS AND METHODS. Values are means  SE from
4 separate experiments. *P  0.05 vs. oxLDL treatment. B: HUVECs were
incubated with oxLDL (150 g protein/ml) in the absence (control) or
presence (oxLDL  GbE) of 50 g/ml GbE for 24 h. The histogram of cell
surface expression of VCAM-1, ICAM-1, and E-selectin was generated by
flow cytometry. Values are means  SE of 3 independent analyses. *P  0.05
vs. oxLDL treatment.
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shown in Fig. 2, oxLDL significantly reduced eNOS protein
expression in HUVECs after 24 h of incubation (39.9%, P 
0.05); however, this tendency was reversed significantly with
GbE pretreatment.
GbE suppressed oxLDL-induced adherence of THP-1 cells
to HUVECs and expression of adhesion molecules. OxLDL-
enhanced recruitment, retention, and adhesiveness of human
monocytes and monocytic cell lines to endothelium have been
implicated in the initial stage of atherogenesis (21). To test the
effect of GbE on monocyte adhesion to HUVECs, confluent
monolayers of HUVECs were pretreated with various concen-
trations of GbE for 2 h and then stimulated with oxLDL (150
g/ml) for 24 h, followed by incubation with THP-1 cells for
1 h at 37°C. As shown in Fig. 3A, oxLDL stimulated an
increase in adherence of THP-1 cells to HUVECs (512 15%,
P  0.05); however, the effect was significantly inhibited by
GbE treatment in a dose-dependent manner (all P  0.05). The
effect of GbE on the surface expression of adhesion molecules
on HUVECs exposed to oxLDL was subsequently examined.
As shown in Fig. 3B, the expression levels of VCAM-1,
ICAM-1, and E-selectin were significantly higher in HUVECs
that had been treated with oxLDL (150 g/ml) for 24 h than in
the control cells (195, 279, and 294%, respectively, compared
with control). Flow cytometry revealed that the induction of
adhesion molecule expression was significantly ameliorated by
the presence of 50 g/ml GbE (all P  0.05).
GbE reduced oxLDL-induced intracellular Ca2 accumula-
tion. To investigate the effect of chronic exposure of endothe-
lial cells to a cytotoxic concentration of oxLDL on intracellular
calcium, we incubated HUVECs with oxLDL (150 g/ml) in
the absence or presence of GbE. As shown in Fig. 4, the basal
level of [Ca2]i increased in oxLDL-treated cells after 24 h,
whereas GbE significantly inhibited the oxLDL-enhanced in-
tracellular calcium rise (all P  0.05).
Effect of GbE on mitochondrial transmembrane permeabil-
ity transition. Because high cytosolic calcium levels can the-
oretically activate several proapoptotic mechanisms mediated
by calcium-dependent enzymes, mitochondrial permeability
transition pore opening, or calcium-induced osmotic swelling/
rupture of mitochondrial membranes (52), it was of interest to
identify the calcium-dependent apoptotic pathways. To exam-
ine whether inhibition of mitochondrial disruption accounts for
the antiapoptotic effect of GbE, we tested the effects of oxLDL
on mitochondrial permeability. When HUVECs were exposed
to oxLDL (150 g/ml), the m was depolarized, as shown by
the increase in green fluorescence (Fig. 5A, middle). Pretreat-
ment with GbE reduced the change in m, as indicated by
repression of green fluorescence and restoration of red fluores-
cence (Fig. 5A, right). Quantitative analysis from flow cytom-
etry supported these findings. As shown in Fig. 5B, oxLDL
caused a marked increase in JC-1 green fluorescence (middle)
compared with the control (left). Pretreatment with GbE caused
marked inhibition of this oxLDL-induced apoptotic index (Fig.
5B, right).
GbE mitigated the proapoptotic effects of oxLDL on Bcl-2
family proteins, mitochondrial cytochrome c release, and
caspase-3 activation. Bcl-2 family proteins are upstream reg-
ulators of mitochondrial membrane potential. Since oxLDL
Fig. 4. Effects of GbE on the oxLDL-induced increase
in cytoplasmic Ca2 levels ([Ca2]i) in fura-2-loaded
HUVECs. Cells were incubated with indicated concen-
trations of GbE for 2 h and then incubated with 150
g/ml oxLDL for an additional 24 h. Images were
processed as indicated in MATERIALS AND METHODS.
Ca2 changes are color coded (see color bar at right)
such that warm colors indicate high [Ca2]i. A: no
treatment. B: oxLDL. C: oxLDL  12.5 g/ml GbE.
D: oxLDL  25 g/ml GbE. E: oxLDL  50 g/ml
GbE. F: oxLDL  100 g/ml GbE. Values represent
means  SE of more than 250 individual cells from 3
separate experiments. *P  0.05 vs. oxLDL treatment.
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depolarized m whereas GbE maintained it, whether GbE
also influenced the equilibrium of Bcl-2 family proteins was
investigated. Immunoblotting studies demonstrated that oxLDL
downregulated the antiapoptotic (Bcl-2) and upregulated the
proapoptotic (Bax) proteins, whereas GbE pretreatment effec-
tively repressed these oxLDL-evoked proapoptotic events (Fig. 6A).
Quantitative analysis ascertained that oxLDL significantly de-
creased the Bcl-2-to-Bax ratio, but GbE pretreatment preserved
this antiapoptotic index (Fig. 6A, bar graph).
It is known that disruption of mitochondrial membrane
function results in the specific release of the mitochondrial
enzyme cytochrome c into the cytosol. Therefore, mitochon-
dria were separated from the cytosolic fraction and detected by
Western blotting. As shown in Fig. 6B, the amount of cyto-
chrome c released into the cytosolic fraction was much greater
in HUVECs that had been incubated with oxLDL for 24 h than
in control cells. The results indicate that GbE significantly
prevented oxLDL-induced release of cytochrome c.
Caspase-3 is a key factor in the execution of mitochondrial
apoptosis (52). To examine whether oxLDL and GbE ulti-
mately influence this factor to modulate apoptosis, we subse-
quently determined the active form of caspase-3 by using fluo-
rescence microscopy and flow cytometry. As shown in Fig. 7A,
active caspase-3 was significantly increased in cells that had
been treated with oxLDL for 24 h. In contrast, the activation of
caspase-3 by oxLDL was suppressed in cells that had been
pretreated with 50 g/ml GbE. The activity of caspase-3 was
confirmed using the EnzChek caspase-3 assay kit. The results
showed that oxLDL significantly upregulated caspase-3 activ-
ity 3.1-fold, whereas GbE pretreatment effectively suppressed
the activity of this apoptotic factor, implying a stimulatory
effect of oxLDL and inhibitory action of GbE on caspase-3
activity.
GbE inhibited oxLDL-induced cytotoxicity of HUVECs.
Phase-contrast microscopy was performed to examine the pro-
tective effects of GbE on morphological features of HUVECs
after exposure to oxLDL. After a 24-h exposure to oxLDL, the
number of shrunken cells or cells with blebbing membranes
was significantly reduced by the presence of GbE (Fig. 8A).
The viability of cells incubated with oxLDL in the absence or
presence of indicated concentrations of GbE was assessed
using the MTT assay, and membrane permeability was assayed
by LDH release. Our results showed that oxLDL significantly
reduced viability and increased membrane permeability in
HUVECs after 24 h of incubation (50 and 399% compared
with control, respectively); however, pretreatment with GbE
inhibited oxLDL-induced cytotoxicity of HUVECs dose de-
pendently (all P  0.05).
GbE inhibited oxLDL-induced apoptosis of HUVECs. To
further ascertain whether cell death induced by oxLDL was an
apoptotic event in HUVECs, oxLDL-treated cells were ana-
lyzed biochemically via TUNEL and DAPI staining assays and
evaluated by microscopic observation and flow cytometry. As
shown in Fig. 9, cells incubated with oxLDL for 24 h showed
typical features of apoptosis, including the formation of con-
densed nuclei, which were, however, not observed in the
GbE-pretreated HUVECs. As described above, cell viability
assay coupled with phenotypic observation of apoptosis under
Fig. 5. Effects of GbE on mitochondrial trans-
membrane permeability transition. Cells were in-
cubated with 50 g/ml GbE for 2 h and then
incubated with 150 g/ml oxLDL for an addi-
tional 24 h. A: the change in mitochondrial mem-
brane potential was assessed based on the signal
intensity from monomeric and J-aggregate JC-1
fluorescence as described in MATERIALS AND
METHODS. Left, no treatment; middle, oxLDL;
right, oxLDL  GbE. B: JC-1 fluorescence
was confirmed by flow cytometry. Green fluo-
rescence intensity indicates the cells with low
m, while the red fluorescence intensity in-
dicated the cells with stable m. Data show a
representative experiment from a minimum of
3 independent experiments.
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microscopy and flow cytometry suggested that GbE is a potent
inhibitor of oxLDL-induced cytotoxicity in cultured HUVECs.
DISCUSSION
There is a growing body of evidence, ranging from in
vitro experiments to pathological analyses and epidemiolog-
ical studies, which indicates the beneficial role of GbE in the
treatment of cardiovascular disease (35, 36); however, its
clinical use is still underrepresented because of the lack of
knowledge about its cellular and molecular mechanisms of
action (60). The aim of the present study was to elucidate
the underlying mechanism by which GbE protects against
oxLDL-induced endothelial dysfunction. The main findings
of this study indicate that the pretreatment with GbE sig-
nificantly suppressed the oxLDL-induced endothelial dys-
function in cultured HUVECs. Of particular interest is the
findings that the protective effects of GbE resulted from
decreased ROS generation that subsequently attenuated the
oxLDL-impaired antioxidant activities and increased the
bioavailability of NO, the maintenance of endothelial
[Ca2]i, and the stabilization of mitochondria, thereby pre-
venting the release of mitochondrial protein cytochrome c, a
molecule required for the activation of caspase-3 that exe-
cutes the cell death program.
Since GbE is a complex mixture of ingredients with a
unique broad spectrum of pharmacological activities, it
probably acts through several different mechanisms cover-
ing ROS scavenger and enhancing SOD activities. For
example, it is a potent superoxide anion scavenger with
SOD activities (40). It also directly activates SOD activity/
synthesis toward reducing free radical formation and stabi-
lizing membranes rather than scavenging free radicals (44).
Previous studies have demonstrated that endothelial dys-
function caused by oxLDL is due to a decrease in antioxi-
dative enzymes (26), thereby inducing apoptosis by activat-
ing multiple ROS-sensitive signaling pathways (29). In
addition, treatment with GbE led to a significant enhance-
ment of cellular SOD activities in keratinocytes (61) and
cardiomyocytes (44). ROS generated by endothelial cells
include O2	, H2O2, peroxynitrite (  ONOO), NO, and hy-
droxyl (  OH) radicals (27). The major source of ROS in
endothelial cells is the NADPH oxidase system (1). Intra-
cellular ROS levels are regulated by the balance between
ROS-generating enzymes and antioxidant enzymes that in-
clude SOD, catalase, and glutathione peroxidase. Blood
vessels express three isoforms of SOD, namely, cytosolic or
Cu, Zn-SOD (SOD-1), Mn-SOD (SOD-2) localized in mito-
chondria, and an extracellular form of Cu,Zn-SOD (EC-SOD;
SOD-3) (13). SOD protects against superoxide-mediated cyto-
toxicity by catalyzing O2	 to form H2O2. Cu,Zn-SOD, but not
Mn-SOD, inactivated by H2O2 produced from superoxide an-
ion (20), plays a key role in atherosclerosis (53). An increase in
activity of Cu,Zn-SOD prevents oxLDL-induced endothelial dys-
function (47). A previous study demonstrated that GbE exhib-
its an activity similar to that of Cu,Zn-SOD; for example, 75
g/ml GbE possesses an activity equal to that observed with
0.22 U Fridovich of bovine Cu,Zn-SOD (40), and a cDNA
microarray study (46) showed that RNA expression of Cu,Zn-SOD,
Fig. 6. Immunoblotting analysis of Bcl-2 family proteins (A) and mitochondrial cytochrome c release (B) in response to oxLDL and GbE. HUVECs were
incubated with 150 g/ml oxLDL in the absence or presence of indicated concentrations (12.5–100 g/ml) of GbE for 24 h. Representative Western blots (left)
and summary data (right) show that oxLDL upregulated proapoptotic (Bax) and downregulated antiapoptotic (Bcl-2) proteins and increased the abundance of
cytochrome c in the cytosolic fraction, whereas GbE pretreatment suppressed these apoptosis-provoking alterations. Results of densitometric analysis are
means  SE of 3 separate experiments. *P  0.05 vs. oxLDL treatment.
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but not Mn-SOD, was increased by GbE. In accordance with
these studies, our results showed that GbE treatment signifi-
cantly reduced ROS generation that subsequently ameliorated
oxLDL-attenuated SOD-1 expression. We assume that the
mechanisms by which GbE protects against oxLDL-induced
endothelial dysfunction could be mainly through the ROS
scavenger with SOD activity.
In many vascular pathologies, a combination of altered
rates of NO production along with an increased removal of
NO leads to an apparent reduction in the bioavailability of
NO. The antithrombotic and antiatherosclerotic properties
of NO are achieved by its ability to inhibit the expression of
the cell surface adhesion molecules P-selectin, VCAM, and
ICAM (23), prevent the expression of monocyte chemoat-
tractant protein (MCP)-1 (57), and inhibit platelet adhesion
under flow conditions (10). In normal physiology, superox-
ide is detoxified by the enzyme SOD, thereby preventing its
interaction with NO. Our data show that GbE ameliorated
the oxLDL-diminished expression of eNOS and had an
inhibitory effect on the oxLDL-induced adhesiveness be-
tween monocytes and HUVECs. We further examined the
inhibitory effects of GbE on the oxLDL-induced surface
expression of adhesion molecules in HUVECs. As expected,
GbE repressed the oxLDL-induced surface expression of
these adhesion molecules. All of these findings strongly
indicate the antioxidative and anti-inflammatory effects of
GbE in response to oxLDL treatment in HUVECs. Our
findings support those of previous reports that demonstrated
µ
µ
Fig. 7. Effects of GbE on oxLDL-induced
caspase-3 activation. HUVECs were incubated
with oxLDL in the absence or presence of
indicated concentrations of GbE for 24 h.
A: fluorescence images show the activated
caspase-3 level in control cells (left), HUVECs
stimulated with oxLDL (middle), and in the
presence of GbE (right). B: fluorescence inten-
sity of cells was measured with flow cytom-
etry. C: the activity of caspase-3 was 3.1-fold
higher in oxLDL-treated HUVECs compared
with the control but was limited to a 2.6- to
0.9-fold increase when pretreated with GbE
(12.5–100 g/ml). Values are means  SE of
3 independent analyses. *P  0.05 vs. oxLDL
treatment.
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the antioxidative effects of GbE derived from inhibition of
ROS production via suppression of NADPH oxidase acti-
vation (28) and the sphingomyelinase ceramide pathway
(31). With regard to the underlying mechanisms of anti-
inflammation, GbE inhibits P-selectin-mediated leukocyte
adhesion and inflammation (14) and acts as a potent inhib-
itor of NF-B, a key transcription factor in the expression of
inflammatory cytokines (6). In addition, recent studies have
shown that ginkgo improves endothelium-dependent vaso-
dilation (54) and reduces doxorubicin-induced apoptotic
damage in rat hearts and neonatal cardiomyocytes (32).
Together, these findings suggest that GbE might be a can-
didate drug for the prevention of cardiovascular diseases.
Although modulation of biological signaling pathways by
ROS depends on both the upstream ligand-dependent stim-
ulation of ROS production and the specific interactions of
ROS with individual downstream pathways, NADPH oxi-
dases seem to be especially important in that they are the
main source whose primary function appears to be to mod-
ulate redox signaling (5). OxLDL rapidly elevates ROS and
then multiple downstream events are activated via second-
ary messengers, including p38 mitogen-activated protein
kinase (MAPK) or phosphoinositide 3-kinase (PI3K), both
causing NF-B activation and enabling nuclear transloca-
tion and subsequent regulation of proinflammatory gene
expression (8). In the present study, GbE at a dose as low as
50 g/ml was sensitive enough to reverse the inhibitory
effect on SOD and eNOS expression but only partially
effective in reducing adhesion molecule expression and
monocytic adherence. We assumed that GbE at this dose
might not be able to abolish completely all of the ROS that
were generated when exposed to oxLDL and/or other down-
stream pathways involved that together led to partial inhi-
bition of adhesion molecule expression.
Pathophysiological stimuli that induce endothelial activa-
tion via NADPH oxidase-mediated ROS-induced signal
transduction and alteration of intracellular Ca2 ion ho-
meostasis are now considered to be major contributors to the
Fig. 8. Effects of GbE on oxLDL-induced endothelial cell
death. A: HUVECs were incubated with oxLDL (150 g
protein/ml) in the absence (middle) or presence (right) of
various concentrations of GbE for 24 h. Photomicrographs are
from phase-contrast microscopy. Viability was determined via
MTT assay (B) and lactate dehydrogenase (LDH) release (C).
Values are means  SE of 3 separate experiments. *P  0.05
vs. oxLDL treatment.
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atherosclerotic coronary artery diseases (33). Endothelial
cells do not possess voltage-operated L-type calcium chan-
nels. Matsui et al. (34) demonstrated that nifedipine, a
calcium channel blocker, decreased advanced glycation end
product-induced MCP-1 overexpression by inhibiting ROS
generation and subsequent NF-B activation via suppres-
sion of NADPH oxidase. Our study found that ROS gener-
ation was the earliest apoptotic signal and that it usually
occurred within 5 min after the addition of oxLDL. There-
fore, we assume that the antiapoptotic effects of GbE were
due to its ability to decrease the level of ROS generation,
which helped maintain the level of mitochondrial [Ca2]i in
endothelial cells, thereby preventing the release of mito-
chondrial protein cytochrome c, a molecule required for the
activation of caspase-3. In addition, the oxLDL-induced
increase in ROS preceded the increase in [Ca2]i (2 vs.
24 h), suggesting that the increase in [Ca2]i induced by
oxidative stress may be a consequence of free radical action
on calcium ions stored in intracellular organelles. Our find-
ing that GbE reduced the level of apoptosis and cell death is
especially relevant because increased endothelial cell apop-
tosis may initiate atherosclerotic lesions (30). Whether in-
hibition of NADPH oxidase is involved in the effect of GbE
on oxLDL-induced ROS generation requires further study.
The concentrations of GbE required to suppress the oxLDL-
induced endothelial dysfunction in our study were similar to
those reported to inhibit other responses, such as smooth
muscle cell proliferation, vascular endothelial growth fac-
tor, thrombomodulin expression, and tissue-type plasmino-
gen activator secretion (24, 28, 58). The dose of GbE used
in previous in vitro studies, which usually ranged from 200
to 400 g/ml, seems to be relatively high compared with the
dose used in the current study. The recommended dose of
GbE injection is 87.5 mg/day for patients with chronic
vascular disease (56). In humans, it is unclear how much the
circulating blood level would be elevated by a single dose of
GbE, since the pharmacokinetics of the components of GbE
have not been completely established. It also is unknown
whether prolonged use of GbE would lead to chronic accu-
mulation of some of the components in different tissues.
In summary, the results from our experiments indicate
that GbE attenuates oxLDL-induced oxidative functional
damages in endothelial cells, probably via its antioxidative
and anti-inflammatory functions, by reducing the oxLDL-
induced ROS generation and impairment of antioxidant
enzymes, the expression of adhesion molecules, and the
adhesiveness between monocytes and HUVECs. In addition,
GbE inhibited oxLDL-induced cell death and apoptosis in
HUVECs. Our work adds GbE to the growing list of herbal
remedies whose mode of action has been at least partially
revealed on a molecular level.
Fig. 9. Effects of GbE on oxLDL-induced endothelial cell
apoptosis. HUVECs were incubated with oxLDL (150 g
protein/ml) in the absence (middle images) or presence (right
images) of 50 g/ml GbE for 24 h. Top images show cells
stained with 4,6-diamidino-2-phenylindole (DAPI); bottom im-
ages show cells stained using terminal deoxynucleotidyl trans-
ferase dUTP-mediated nick-end labeling (TUNEL) assay. Ar-
rows indicate condensed nuclei. Graph displays flow cytomet-
ric analysis. Data show a representative experiment from a
minimum of 3 independent experiments.
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